The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation

The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation

Abstract Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors....

Full description

Bibliographic Details
Main Authors: Agnieszka Strumidło, Sylwia Skiba, Rodney J. Scott, Jan Lubiński
Format: Article
Language:English
Published: BMC 2017-09-01
Series:Hereditary Cancer in Clinical Practice
Subjects:
Breast cancer
Ovarian cancer
BRCA1
microRNA
Treatment
Online Access:http://link.springer.com/article/10.1186/s13053-017-0076-7
Description
Summary:Abstract Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors. Recent studies demonstrated that microRNAs - small non-coding RNAs, involved in the control of gene expression, can decrease BRCA1 expression by targeting the 3’UTR region of the gene. This article reviews reported relationships between various miRNAs, such as miRNA-9, miRNA-146a, miRNA-182 miRNA-218, miRNA-638 and the response to cytostatic drugs, mainly to platins and PARP1 inhbitors, for the treatment of breast and ovarian cancer associated with BRCA1 mutations.
ISSN:1897-4287

Similar Items